PASADENA, CA, August 18, 2026 — Akari Medspa announced the introduction of a structured Daxxify treatment approach for adults seeking temporary improvement of moderate-to-severe glabellar lines. The process incorporates medical history review, dynamic facial assessment, individualized treatment planning, informed consent, and follow-up guidance.

The updated approach reflects patient interest in neuromodulator treatment with longer maintenance intervals. Daxxify is an FDA-approved injectable neuromodulator for moderate-to-severe glabellar lines in adults, with pivotal clinical trials reporting a median response duration of approximately 24 weeks. Individual duration varies based on factors including metabolism, dose, muscle activity, treatment area, and injection technique.

Akari Medspa begins treatment planning with a documented medical consultation and history review. The assessment considers allergies, medications, previous neuromodulator treatment, relevant medical conditions, contraindications, facial anatomy, and treatment goals before an individualized plan is established.

The practice also uses dynamic facial assessment to evaluate muscle movement, brow position, eyelid anatomy, asymmetry, and baseline lines. Providers observe facial movement and assess relevant muscles to determine treatment areas while considering the amount of movement a patient intends to preserve.

Treatment planning includes discussion of target areas, expected movement, dose, cost, alternatives, potential adverse effects, and whether Daxxify or another neuromodulator is appropriate. Clinical photography may also be used with consent to document baseline appearance and support subsequent assessment.

Daxxify treatment visits generally take 20 to 30 minutes following consultation, with the injection portion commonly lasting five to 10 minutes. The practice provides individualized aftercare instructions and evaluates the full early outcome at approximately 10 to 14 days. Follow-up timing is based on observed movement and individual treatment goals rather than a standardized maintenance calendar.

The treatment workflow also distinguishes neuromodulator use from services addressing facial volume or skin quality. Daxxify temporarily reduces targeted muscle activity and does not add facial volume. Akari Medspa may evaluate other treatment categories when facial concerns are associated with volume loss, contour, texture, or other factors rather than muscle movement.

Akari Medspa will continue using individualized assessment, treatment planning, documented consent, and follow-up guidance as part of its Daxxify services while monitoring patient response and adjusting future treatment intervals according to individual movement patterns and treatment objectives.

Media Contact

Akari Medspa
Phone: (949) 628-6949
Email: info@akarimedspa.com
Website: Akari Medspa

About Akari Medspa

Akari Medspa provides aesthetic treatment services for patients in Pasadena and surrounding communities, including neuromodulator and facial treatment options. The practice uses documented consultations, individualized assessment, treatment planning, informed consent, and follow-up guidance as part of its approach to injectable services.

Contact Information:

Akari Medspa

2382 SE Bristol St Suite B1
Newport Beach, CA 92660
United States

Izzy Koo
(949) 694-7220
http://akarimedspa.com